ASH Clinical News

@ASHClinicalNews

A magazine from offering news and views for the broader hematology/oncology community.

Vrijeme pridruživanja: listopad 2014.

Tweetovi

Blokirali ste korisnika/cu @ASHClinicalNews

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ASHClinicalNews

  1. proslijedio/la je Tweet
    3. velj

    Well written and detailed article from on the costs for treatment of hemophila, including quotes from .

    Poništi
  2. Toot Your Own Horn: In a review of approximately 6.2 million life sciences articles published between 2002 and 2017, woman researchers were 12.3% less likely than men to frame their work positively

    Poništi
  3. We asked , other specialists, and hemophilia treatment center administrators why the price tags for treatment of this rare disease are so uncommonly high

    Poništi
  4. 3. velj

    The February issue discusses the high price of treating , debates whether CAR T-cell therapies are worth the costs, and more

    Poništi
  5. 31. sij
    Poništi
  6. 30. sij

    After 3 years of follow-up, ECHELON-1 investigators report that the benefits of brentuximab vedotin are sustained and consistent across risk subgroups in patients with advanced Hodgkin

    Poništi
  7. 30. sij

    Transfusion Confusion: A study in found that for critically ill pediatric patients needing red blood cell transfusions, there was no significant difference in the proportion of patients developing organ dysfunction according to the “freshness” of the blood product used

    Poništi
  8. 29. sij

    Time-limited frontline therapy with acalabrutinib, venetoclax, and obinutuzumab leads to encouraging rates of complete remission with high rates of undetectable measurable residual disease in chronic lymphocytic ()

    Poništi
  9. 29. sij

    “These results suggest future trials may liberalize comorbidity and organ function eligibility criteria, which will likely improve recruitment rates and provide equitable access to investigational products.” – from

    Poništi
  10. 28. sij

    Written in : In patients with acute myeloid () with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1+ fusion, serial assessment of measurable residual disease can identify people at a high risk for relapse during treatment and follow-up

    Poništi
  11. 28. sij

    Is Age Just a Number? More older patients with multiple are undergoing transplantation and deriving the same benefit as younger patients, although it has previously been deemed too risky for patients >70 years

    Poništi
  12. 27. sij

    The and partnered to bring hematologists practical information about newly approved agents during the “ASH-FDA Symposium on New and Late-Breaking Drug Approvals” at

    Poništi
  13. 27. sij

    Presented by from at : Bispecific antibody CC-93269 was reported to have a “manageable” safety profile in patients with heavily pretreated multiple , although several patients developed cytokine release syndrome

    Poništi
  14. 24. sij

    Correcting Cancer Care Chasms: A report from shows that hands-on interventions to improve access to care can help correct racial disparities in outcomes.

    Poništi
  15. 24. sij

    A Los Angeles jury found that Yescarta from Gilead’s Kite Pharma unit infringed on a patent exclusively licensed from Memorial Sloan Kettering by Bristol-Myers’ Juno Therapeutics division

    Poništi
  16. 24. sij

    According to results from the ZUMA-2 trial presented by from at , 93% of patients with rel/ref mantle cell () responded to treatment with KTE-X19

    Poništi
  17. 23. sij

    Older patients who were evaluated in a multidisciplinary team clinic after stem cell transplantation experienced shorter inpatient stays, fewer nursing home admissions, and better early survival rates

    Poništi
  18. 23. sij

    Incomes and Outcomes: Researchers examined clinical trial and socioeconomic data from 1,467 children enrolled in 2 acute myeloid () trials and found that those from poorer neighborhoods were 2.4x more likely to die during treatment.

    Poništi
  19. 23. sij

    The is struggling to complete inspections of foreign drug manufacturing facilities with only 12 inspectors currently based overseas

    Poništi
  20. 22. sij

    Presented by Stephen J. Schuster, MD from at : Mosunetuzumab led to durable responses in patients with B-cell non-Hodgkin (), even in those who had disease that was relapsed or refractory to CAR T-cell therapy

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·